SynAct Pharma
Lund
About SynAct Pharma
SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected to be available during Q2 2018. The company intends to prepare for a first patient study in parallel with the completion of the phase I study. Assuming that AP1189 has proven safe and tolerable also in multiple dosing, the aim is to submit a clinical trial application (CTA) in patients with active arthritis (joint inflammation). After proof of concept has been shown in patients, the company intends to sign commercial agreements with one or more major pharmaceutical companies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $7.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: fra:8F8
- Website: synactpharma.comsv
- Phone: +45 28 44 75 67
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/synact-pharma-31092 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.